SCHEMBL443246

SCHEMBL443246

CCCCCNC(=O)OC

nearest known ligand 0.95

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 6/20 0.95
ACHE P22303 8/20 0.59
CASP2 P42575 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10118264 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL28556990 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL717504 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL28335637 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL13387440 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL13387508 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL3910901 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL1616893 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL22693961 0.98 EPHX1 (1.00) EPHX1ACHECASP2
SCHEMBL27052567 0.98 EPHX1 (1.00) EPHX1ACHECASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687490-B2 2-thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2010-03-30 US claimed
EP-1870412-A1 2-THIOETHENYL CARBAPENEM DERIVATIVE MEIJI SEIKA KAISHA LTD. (JP) 2007-12-26 EP claimed
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2007-01-04 US claimed
EP-0521827-B1 Pharmacological active hydrazin derivatives and process for their preparation CIBA GEIGY AG (CH) 1996-09-25 EP claimed
EP-0241735-A2 Acyloxythiophene carbon amide BAYER AG (DE) 1987-10-21 EP claimed
EP-4325622-A1 SECONDARY BATTERY ELECTROLYTE SOLUTION AND SECONDARY BATTERY Murata Manufacturing Co., Ltd. (JP) 2024-02-21 EP disclosed
US-20230174483-A1 INDIRUBIN DERIVATIVES, AND USES THEREOF CITY OF HOPE (US) 2023-06-08 US disclosed
US-20230174483-A1 INDIRUBIN DERIVATIVES, AND USES THEREOF CITY OF HOPE (US) 2023-06-08 US disclosed
US-11524937-B2 Indirubin derivatives, and uses thereof CITY OF HOPE (US) 2022-12-13 US disclosed
WO-2022255018-A1 SECONDARY BATTERY ELECTROLYTE SOLUTION AND SECONDARY BATTERY 株式会社村田製作所 2022-12-08 WO disclosed
CN-109641835-B Method for producing carbamate 国立研究开发法人产业技术综合研究所 2021-07-20 CN disclosed
EP-3508473-B1 METHOD FOR PRODUCING CARBAMIC ACID ESTER AIST (JP) 2021-05-26 EP disclosed
EP-0420520-A1 Pesticidal compositions ROUSSEL-UCLAF (FR) 1991-04-03 EP disclosed
EP-0119954-B1 3-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE CIBA-GEIGY AG (CH) 1990-03-14 EP disclosed
EP-0119161-B1 BENZAZOCINONE AND BENZAZONINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR THERAPEUTICAL USE CIBA-GEIGY AG (CH) 1989-06-28 EP disclosed
EP-0241735-A2 Acyloxythiophene carbon amide BAYER AG (DE) 1987-10-21 EP disclosed
US-4477464-A Hetero-benzazepine derivatives and their pharmaceutical use CIBA-GEIGY CORPORATION (US) 1984-10-16 US disclosed
EP-0119954-A2 3-Amino-1-benzazepin-2-one-1-alcanoic acids, process for their preparation, their pharmaceutical preparation as well as their therapeutic use CIBA-GEIGY AG (CH) 1984-09-26 EP disclosed
EP-0119161-A2 Benzazocinone and benzazoninone derivatives, process for their preparation, pharmaceutical preparations containing these compounds, and their therapeutical use CIBA-GEIGY AG (CH) 1984-09-19 EP disclosed
US-4386033-A BOILING, CONDENSATION OF VAPORS, CIRCULATION; SEPARATION BAYER AKTIENGESELLSCHAFT (DE) 1983-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174483-A1 INDIRUBIN DERIVATIVES, AND USES THEREOF HCCS, ABL1, MAP3K7 EPHX1 3329/4885ACHE 4073/4885CASP2 2364/4885
US-11524937-B2 Indirubin derivatives, and uses thereof HCCS, ABL1, MAP3K7 EPHX1 3329/4885ACHE 4073/4885CASP2 2364/4885
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MTAP, BLVRB, BPGM EPHX1 3352/4885ACHE 2739/4885CASP2 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.